Approximately 30% of lung adenocarcinomas harbor KRAS mutations [89,91,118], with the G12C variant being the most prevalent, comprising about 40% of KRAS-altered NSCLC cases [119]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.